RE:RE:RE:RE:Trying to look at the positivesThis was answered in the Q&A section of their call. They said that roughly half the R&D ends shortly and will fall out of the numbers. I believe Dubuc said that the full year line would look like 2021 which was around $28mil and had some one-offs in it too. So that would be a drop of $10-12mil. Then tighter expense control, so assume something in the SGA line drops out (there were probably a few consultant fees around NASH and such in 2022 so plenty of room to save $3-4mil). Then you have revenue growth of $10mil at low end of target. So all in that's a shift of $12+$10+$3, or around $25mil delta. It could be higher if revs hit high end or they get more aggressive, which I think they will. They may have substituted some cash comp for options grants and they clearly are finding a way to harbor a lot more cash as the year end cash figure was much higher than anticipated. I believe there is an ongoing benefit on the Trogarzo inventory and new manufacturer being more a "just in time" system so no need for future inv build. That frees up all that inventory cash and lowers expenses some too.
So I think you need to go back and listen to the report and read an analyst report. There's a large swing they already have identified they are doing. Now the market just needs to see evidence of this and they've said the quarter is "on target" for their projected budget. That budget is for 10-15% sales growth and lower expenses, so we'll see.